Boston Scientific Corporation (BSX) Expected to Post Quarterly Sales of $2.34 Billion
Brokerages predict that Boston Scientific Corporation (NYSE:BSX) will report sales of $2.34 billion for the current quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Boston Scientific’s earnings, with the lowest sales estimate coming in at $2.32 billion and the highest estimate coming in at $2.36 billion. Boston Scientific reported sales of $2.16 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.3%. The business is scheduled to issue its next earnings report on Thursday, April 26th.
According to Zacks, analysts expect that Boston Scientific will report full year sales of $2.34 billion for the current fiscal year, with estimates ranging from $9.70 billion to $9.77 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $10.32 billion per share, with estimates ranging from $9.90 billion to $10.54 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Boston Scientific.
Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The company had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. During the same quarter in the prior year, the business posted $0.30 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year.
In other Boston Scientific news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of Boston Scientific stock in a transaction that occurred on Tuesday, November 28th. The stock was purchased at an average cost of $0.45 per share, with a total value of $183,602.70. Also, SVP David A. Pierce sold 5,152 shares of the stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the sale, the senior vice president now directly owns 38,116 shares of the company’s stock, valued at $1,029,132. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,464 shares of company stock valued at $4,253,617. Company insiders own 0.74% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Sit Investment Associates Inc. lifted its stake in Boston Scientific by 37.8% in the 3rd quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after acquiring an additional 38,855 shares in the last quarter. Greenwood Capital Associates LLC increased its position in Boston Scientific by 71.7% in the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock worth $2,671,000 after purchasing an additional 38,249 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in Boston Scientific by 94.9% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock worth $1,126,000 after purchasing an additional 18,800 shares during the last quarter. LS Investment Advisors LLC increased its position in Boston Scientific by 5.8% in the 3rd quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock worth $1,185,000 after purchasing an additional 2,209 shares during the last quarter. Finally, Chevy Chase Trust Holdings Inc. increased its position in Boston Scientific by 1.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,197,587 shares of the medical equipment provider’s stock worth $34,934,000 after purchasing an additional 16,992 shares during the last quarter. 90.15% of the stock is owned by hedge funds and other institutional investors.
Boston Scientific (NYSE BSX) opened at $25.92 on Monday. Boston Scientific has a 52 week low of $23.29 and a 52 week high of $29.93. The stock has a market capitalization of $35,590.00, a price-to-earnings ratio of 370.29, a PEG ratio of 1.88 and a beta of 0.81. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.